Multiple sclerosis (MS) is an inflammatory demyelinating
Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS) and in western countries the most common cause of acquired disability in adulthood. Bouts of CNS inflammation and demyelination are the pathological hallmarks of the acute disease. 1 The main cause of persistent disability seems to be ongoing axonal loss due to demyelination and degeneration 2 and the failure of myelin repair due to impairment of oligodendrocyte progenitor cells to generate mature oligodendrocytes. 3 As evidenced from myelogenesis in rat brain, 4 growth factors like platelet derived growth factor A (PDGF-A), fibroblast growth factor 2 (FGF-2), ciliary neurotrophic factor (CNTF), transforming growth factor beta 1 (TGF-beta 1), insulin-like growth factor 1 (IGF-1) and neurotrophin-3 (NT-3) combine to regulate myelination and remyelination in brain aggregate cultures. While CNTF was initially characterized as a trophic factor for neurons [5] [6] [7] more recent evidence supports the role for survival, proliferation, and maturation of oligodendrocyte lineage cells. 8 In addition CNTF protects oligodendrocytes from TNF-␣ induced cell death. 9 and was found to be increased in cerebrospinal fluid (CSF) of MS patients recovering from acute exacerbations. Recently a mutation in the human CNTF gene 11 located on chromosome 11q12.2 has been described. 6 The G to A transition at position −6 of the acceptor splice site leads to the insertion of four additional ribonucleotides at the beginning of the next exon which results in a frameshift and a premature stop codon (CNTF, IVS1AS, G-A, -6, 4-BP INS, FS63TER). The truncated protein was not detectable in the peripheral nerve tissue of individuals homozygous for the null mutation. 6 This genotype, however, was not causally related to neurological diseases like amyotrophic lateral sclerosis, Alzheimer disease or Parkinson disease. 6 Since CNTF plays a role in cell survival, maturation and remyelination CNTF could be one of the candidate genes, predisposing for MS or modifying the course of the disease.
CNTF-genotypes were determined in DNA samples of 349 hospitalized MS-patients and 434 apparently healthy blood donors. MS patients and controls had been HLA-DRB1* typed as described previously. 12 As shown in Table 1 CNTF-genotype frequencies were similar in MS patients and controls and frequencies did not change significantly after stratification for HLA-DRB1* alleles, ie, HLA-DRB1*15 or HLA-DRB1*03.
The clinical diagnosis of MS suggests a homogeneous disease entity, but in terms of pathology, clinical course and genetic susceptibility MS is certainly a heterogeneous disease. Therefore we analysed the impact of the CNTF mutation on the clinical presentation of the disease. According to the development of symptoms over time patients were classified as having 'relapsing-remitting' *OR, odds ratio; **CI, confidence interval; ***P-value. DNA samples were amplified by polymerase chain reaction (PCR) according to standard protocols with a forward primer (5′-CCTTGGCCAGTGAGATGAGTGAG-3′) located in the first intron and a reverse primer (5′-CTTGAAGGTTCTCTTGGAGT-3′) located in the second exon of the CNTF gene. 11 The wild-type and mutant alleles were discriminated by Allele-Specific-Oligonucleotide (ASO) hybridization essentially as described 12 utilizing the ASO (5′-TCACCTGGCCGAGGATACA-3′) for the wildtype and ASO (5′-TCACCTGGCTGAGGATACA-3′) for the mutant allele. Genotype frequencies were determined as described previously.
(RRMS), 'primary progressive' (PPMS) or 'secondary progressive' MS (SPMS)
. 13 Patients were further classified by age of first symptoms of the disease as 'early onset' (Ͻ15 years), 'average onset' (у15 to 40 years) and 'late onset' (у40 years).
14 Finally patients were subgrouped according to the severity of MS. Severity of the disease was defined as the rate of accumulation of neurologic disability in patients with a disease duration у5 years and expressed as progression index (PI=EDSS/disease duration in years). 15 According to this definition disease was considered as 'less severe' (PI Ͻ 0.5), 'moderately severe' (PI = 0.5-1) and 'severe' (PI Ͼ 1).
As shown in Table 1 , the number of MS patients homozygous for the CNTF-null mutation (genotype 0202) was too small for statistical evaluation. We therefore compared the presentation of clinical features in MS patients, homozygous for the CNTF-genotype 0101 with those who were heterozygous (0102) and considered to produce less CNTF protein. 6 The CNTF-genotype 0101 was found in 241 MS-patients, 47.7% had a relapsing remitting, 33.2% a secondary progressive and 19.1% a primary progressive course of the disease. Similar results were obtained for 74 patients with the CNTF-genotype 0102 (Table 2) . Stratification for gender revealed a male to female ratio of 1:2.6 for patients with the CNTF-genotype 0101 and of 1:2.1 for patients with the CNTF-genotype 0102. The sexratio was ෂ1:2 in RRMS patients and ෂ1:3 in SPMS patients for both CNTF genotypes. In PPMS patients the male to female ratio was ෂ1:3 for patients with the CNTF genotype 0101 and 1:0.8 for patients with the CNTF genotype 0102, the deviation is not statistical significant. Without stratification for the CNTF-genotype the male to female sex-ratio was ෂ1:2 for RRMS, ෂ1:3 for SPMS and ෂ1:2 for PPMS (data not shown). The frequency of patients with early or late onset of the disease and clinical course of RRMS, SPMS or PPMS was not different in patients homozygous for the CNTF 01 allele or those heterozygous for the CNTF alleles 01 and 02. Finally the CNTF-genotype was not correlated with disease progression, ie, similar frequencies were obtained for patients classified as having less severe, moderately severe or severe MS.
Given the fact that in MS patients the mutant CNTF allele did not accumulate in any subgroup of patients, the role of the CNTF-mutation has to be questioned for MS. One explanation would be that a second ligand located on a different chromosomal region binds to the CNTF-receptor ␣-component and takes over in the absence of sufficient amounts of CNTF. The cardiotrophin-like cytokine/cytokine-like factor-1composite cytokine may be a functionally important second ligand 16 but so far its role in embryonal neuronal development and adult life is ill defined. On the other hand redundancy of neurotrophic factors involved in myelogenesis 4 may explain why reduction or even lack of functional CNTF protein is tolerated so well. The oligodendroglial survival factor, PDGF-AA which activates similar JAK/STAT signaling pathways may be one of the candidate genes. 17 Other candidate genes like FGF-2, TGF-beta 1, IGF-1 and NT-3 have been screened for certain polymorphisms but so far were not shown to be associated with the disease. 18 Since the physiological role of neurotrophic factors is not completely understood, one cannot rule out, that under certain circumstances (mutations in other genes), CNTF may be the limiting factor in MS or other neurological diseases. 
